Altunan, B; Ünal, A; Efendi, H; Köseoglu, M; Terzi, M; Kotan, D; Tamam, Y; Boz, C; Güler, S
(2023)
Background: Follow-on disease modifying therapies (FO-DMTs) do not always require Phase III studies. There are concerns that cheaper FO-DMTs are only used to reduce healthcare costs. However, the well-being of people with ...